Track topics on Twitter Track topics that are important to you
Summit Therapeutics plc
(‘Summit’ or the ‘Company’)
Oxford, UK, and Cambridge, MA, US, 11 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism antibiotic innovation, announces that Valerie Andrews, a Non-Executive Director, is stepping down from the board of the Company with effect from today. The Board will continue to assess its composition to ensure it is supporting the future development of the business.
Dr Frank Armstrong, Chairman of Summit Therapeutics, commented: “I would like to recognise Val’s considerable contribution to Summit and thank her for her commitment to the Company over the last five years. Val has provided valuable insight and expertise in her roles across the Board and committees. We all wish her every success for the future.”
Ms. Valerie Andrews added: “It has been a privilege to play a role in supporting the growth and development of Summit. With the Company’s dedication to developing new class, targeted antibiotics that focus on better outcomes for patients, I believe that the Company is well positioned to fulfil its undoubted promise in this important field of medical research.”
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.
Glyn Edwards / Richard Pye (UK office)
Michelle Avery (US office)
|Tel: +44 (0)1235 443 951|
+1 617 225 4455
|Cairn Financial Advisers LLP (Nominated Adviser)|
Liam Murray / Tony Rawlinson / Ludovico Lazzaretti
|Tel: +44 (0)20 7213 0880|
|N+1 Singer (Joint Broker)|
Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking
|Tel: +44 (0)20 7496 3000|
|Bryan Garnier & Co Limited (Joint Broker)|
Phil Walker / Dominic Wilson
|Tel: +44 (0)20 7332 2500|
|MSL Group (US)|
|Tel: +1 781 684 6652|
|Consilium Strategic Communications (UK)|
Mary-Jane Elliott / Sue Stuart /
Sukaina Virji / Lindsey Neville
|Tel: +44 (0)20 3709 5700|
Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...
BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...